Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

VENLAFAXINE HCL

All products: general benefit

Other products in the same Health Canada class (N06AX) — coverage varies; not interchangeable

  • Duloxetine (Cymbalta): general benefit, Not a benefit
  • Mirtazapine (Remeron RD): general benefit, Not a benefit
  • Trazodone (Desyrel): general benefit, Not a benefit
  • Vortioxetine (Trintellix): general benefit
  • Bupropion (Wellbutrin XL): limited Use 315, Not a benefit
  • Desvenlafaxine (Pristiq): not a benefit

17 more in the class list below

Effexor XR · DIN 02237282 · 150mg · extended release capsule

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Effexor XR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Effexor XR · DIN 02237282 Manufacturer: Upjohn Canada ULC; listing date 2000-01-17 Health Canada: Marketed since 2023-08-09 · brand EFFEXOR XR · ATC N06AX16 VENLAFAXINE · form Capsule (extended-release) · route Oral · ingredients VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 150 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1927 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60603 · Verify on the e-Formulary ↗ (DIN 02237282)

Source record
DIN 02237282: Effexor XR Raw flags: sec3=Y Item: 281604089; group id 474; item number 1195; lccId None; manufacturer id UJC Source form: ER Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $2.4546; ministry $0.1927 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237282 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60603
Interchangeable products
ACT Venlafaxine XR · DIN 02304333 · $0.1927 Apo-Venlafaxine XR · DIN 02331705 · $0.1927 Auro-Venlafaxine XR · DIN 02452855 · $0.1927 M-Venlafaxine XR · DIN 02471302 · $0.1927 Mint-Venlafaxine XR · DIN 02522993 · $0.1927 PMS-Venlafaxine XR · DIN 02278561 · $0.1927 PMSC-Venlafaxine XR · DIN 02521474 · $0.1927 Sandoz Venlafaxine XR · DIN 02310333 · $0.1927 Taro-Venlafaxine XR · DIN 02380099 · $0.1927 Teva-Venlafaxine XR · DIN 02275058 · $0.1927 Venlafaxine XR · DIN 02354748 · $0.1927 Venlafaxine XR · DIN 02385945 · $0.1927 Venlafaxine XR · DIN 02489694 · $0.1927 Venlafaxine XR · DIN 02516551 · $0.1927
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab

TRAZODONE HYDROCHLORIDE

· 17 products · Listed, not a benefit (3), General benefit (14) · strengths: 50mg, 100mg, 150mg · Tab

VORTIOXETINE HYDROBROMIDE

· 6 products · General benefit · strengths: 5mg, 10mg, 20mg · Tab

BUPROPION HCL

· 12 products · Limited Use, codes 315 (10), Listed, not a benefit (2) · strengths: 150mg, 300mg, 100mg · ER Tab, Tab

DESVENLAFAXINE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 100mg · ER Tab

VILAZODONE HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 20mg, 40mg · Tab

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: anxiety disorder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ALPRAZOLAM · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) Generalized Anxiety Disorder XANAX and XANAX TS are indicated for the treatment of Generalized Anxiety Disorder (GAD). PM: https://pdf.hres.ca/dpd_pm/00070545.PDF; date not captured; DIN 00548359; fetched 2026-09-10 Product monograph DULOXETINE · Listed, not a benefit (2), General benefit (36) • Generalized Anxiety Disorder pms-DULOXETINE is indicated for the symptomatic relief of anxiety causing clinically significant distress in patients with generalized anxiety disorder (GAD). PM: https://pdf.hres.ca/dpd_pm/00084896.PDF; date 2026-05-29; DIN 02429446; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS EFFEXOR XR (venlafaxine hydrochloride extended release capsules) is indicated for the symptomatic relief of: • Major depressive disorder • Anxiety causing clinically significant distress in patients with generalized anxiety disorder (GAD). Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. • Social anxiety disorder, also known as social phobia. • Panic disorder, with or without agoraphobia, as defined in DSM-IV Long-term use of EFFEXOR XR: The physician who elects to use EFFEXOR XR for extended periods in the treatment of depression, GAD, social anxiety disorder, or panic disorder should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see 4.1 Dosing Considerations; 4.2 Recommended Dose and Dosage Adjustment). 1.1 Pediatrics Pediatrics (< 18 years of age): Health Canada has not authorized an indication for pediatric use (see 7 WARNINGS AND PRECAUTIONS, Psychiatric, Potential Association With Behavioural And Emotional Changes, Including Self-Harm). 1.2 Geriatrics Geriatrics (> 65 years of age): Caution should be exercise… https://pdf.hres.ca/dpd_pm/00073109.PDF PM date: AUG 09, 2023 Source product: EFFEXOR XR; DIN 02237279; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.